Wellington Management Group LLP Has $59.56 Million Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)

Wellington Management Group LLP grew its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 4.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 25,345,680 shares of the company's stock after purchasing an additional 1,125,454 shares during the quarter. Wellington Management Group LLP owned about 9.53% of Autolus Therapeutics worth $59,562,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. Dumont & Blake Investment Advisors LLC acquired a new stake in Autolus Therapeutics during the 4th quarter worth $35,000. Arkadios Wealth Advisors acquired a new stake in Autolus Therapeutics during the 4th quarter worth $47,000. Daiwa Securities Group Inc. raised its stake in shares of Autolus Therapeutics by 55.5% in the 4th quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock valued at $56,000 after purchasing an additional 8,479 shares during the period. Avanza Fonder AB acquired a new stake in shares of Autolus Therapeutics in the 4th quarter valued at about $75,000. Finally, Handelsbanken Fonder AB raised its stake in shares of Autolus Therapeutics by 30.9% in the 4th quarter. Handelsbanken Fonder AB now owns 73,300 shares of the company's stock valued at $172,000 after purchasing an additional 17,300 shares during the period. Institutional investors and hedge funds own 72.83% of the company's stock.

Autolus Therapeutics Trading Down 3.7 %

Shares of NASDAQ AUTL traded down $0.05 during mid-day trading on Thursday, hitting $1.17. The company had a trading volume of 459,205 shares, compared to its average volume of 1,431,450. Autolus Therapeutics plc has a one year low of $1.14 and a one year high of $5.43. The company has a market capitalization of $310.00 million, a PE ratio of -0.96 and a beta of 2.06. The firm has a 50-day simple moving average of $1.78 and a two-hundred day simple moving average of $2.65.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.12. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $2.98 million. Sell-side analysts expect that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on AUTL shares. Needham & Company LLC reissued a "buy" rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research note on Thursday. Wells Fargo & Company dropped their price target on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a research note on Friday, March 21st. Finally, Truist Financial decreased their price objective on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Autolus Therapeutics has a consensus rating of "Buy" and a consensus price target of $9.32.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.